JP2018529380A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018529380A5 JP2018529380A5 JP2018534523A JP2018534523A JP2018529380A5 JP 2018529380 A5 JP2018529380 A5 JP 2018529380A5 JP 2018534523 A JP2018534523 A JP 2018534523A JP 2018534523 A JP2018534523 A JP 2018534523A JP 2018529380 A5 JP2018529380 A5 JP 2018529380A5
- Authority
- JP
- Japan
- Prior art keywords
- flt3
- car
- nucleic acid
- isolated
- isolated nucleic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 20
- 150000007523 nucleic acids Chemical class 0.000 claims 16
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 14
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 14
- 102000039446 nucleic acids Human genes 0.000 claims 14
- 108020004707 nucleic acids Proteins 0.000 claims 14
- 210000004027 cell Anatomy 0.000 claims 12
- 108091033319 polynucleotide Proteins 0.000 claims 12
- 102000040430 polynucleotide Human genes 0.000 claims 12
- 239000002157 polynucleotide Substances 0.000 claims 12
- 239000013598 vector Substances 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 230000000295 complement effect Effects 0.000 claims 4
- 108020004999 messenger RNA Proteins 0.000 claims 4
- 230000011664 signaling Effects 0.000 claims 4
- 238000011144 upstream manufacturing Methods 0.000 claims 4
- 230000000139 costimulatory effect Effects 0.000 claims 3
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 239000013603 viral vector Substances 0.000 claims 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000002798 bone marrow cell Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000004940 costimulation Effects 0.000 claims 1
- 239000008367 deionised water Substances 0.000 claims 1
- 229910021641 deionized water Inorganic materials 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 238000011534 incubation Methods 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 230000002463 transducing effect Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021189789A JP2022046461A (ja) | 2015-09-23 | 2021-11-24 | 免疫療法のためのｆｌｔ３指向ｃａｒ細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562222695P | 2015-09-23 | 2015-09-23 | |
| US62/222,695 | 2015-09-23 | ||
| PCT/US2016/053577 WO2017053889A2 (en) | 2015-09-23 | 2016-09-23 | Flt3 directed car cells for immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021189789A Division JP2022046461A (ja) | 2015-09-23 | 2021-11-24 | 免疫療法のためのｆｌｔ３指向ｃａｒ細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018529380A JP2018529380A (ja) | 2018-10-11 |
| JP2018529380A5 true JP2018529380A5 (enExample) | 2019-10-31 |
| JP7054924B2 JP7054924B2 (ja) | 2022-04-15 |
Family
ID=58387435
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018534523A Active JP7054924B2 (ja) | 2015-09-23 | 2016-09-23 | 免疫療法のためのｆｌｔ３指向ｃａｒ細胞 |
| JP2021189789A Pending JP2022046461A (ja) | 2015-09-23 | 2021-11-24 | 免疫療法のためのｆｌｔ３指向ｃａｒ細胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021189789A Pending JP2022046461A (ja) | 2015-09-23 | 2021-11-24 | 免疫療法のためのｆｌｔ３指向ｃａｒ細胞 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10961312B2 (enExample) |
| EP (2) | EP3352784A4 (enExample) |
| JP (2) | JP7054924B2 (enExample) |
| KR (1) | KR20180053744A (enExample) |
| CN (1) | CN109310744A (enExample) |
| AU (2) | AU2016326721C1 (enExample) |
| CA (1) | CA2999037A1 (enExample) |
| HK (1) | HK1258921A1 (enExample) |
| WO (1) | WO2017053889A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7054924B2 (ja) * | 2015-09-23 | 2022-04-15 | サイトイミューン セラピューティクス， インコーポレイテッド | 免疫療法のためのｆｌｔ３指向ｃａｒ細胞 |
| AU2017271606B2 (en) | 2016-05-27 | 2024-08-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | FLT3-specific chimeric antigen receptors and methods using same |
| WO2018119279A1 (en) * | 2016-12-21 | 2018-06-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies specific for flt3 and uses thereof |
| CA3053539A1 (en) | 2017-02-27 | 2018-08-30 | Juno Therapeutics, Inc. | Compositions, articles of manufacture and methods related to dosing in cell therapy |
| MY201327A (en) * | 2017-06-02 | 2024-02-16 | Pfizer | Chimeric antigen receptors targeting flt3 |
| EP3630841A1 (en) * | 2017-06-02 | 2020-04-08 | Pfizer Inc. | Antibodies specific for flt3 and their uses |
| CN111542323A (zh) * | 2017-08-01 | 2020-08-14 | 尤利乌斯·马克西米利安维尔茨堡大学 | Flt3 car-t细胞和flt3抑制剂在治疗急性髓细胞性白血病中的用途 |
| EP3662055A1 (en) * | 2017-08-02 | 2020-06-10 | Autolus Limited | Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed |
| WO2019089855A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Process for generating therapeutic compositions of engineered cells |
| CN118530373A (zh) * | 2017-11-10 | 2024-08-23 | 朱拉生物公司 | 基于主要组织相容性复合物的嵌合受体和其用于治疗自身免疫性疾病的用途 |
| CN109988759A (zh) * | 2017-12-29 | 2019-07-09 | 上海细胞治疗研究院 | 一种在t细胞中具有高转录活性的嵌合启动子 |
| US20190328785A1 (en) * | 2018-04-30 | 2019-10-31 | The Board Of Regents Of The University Of Oklahoma | Flt3-binding chimeric antigen receptors, cells, and uses thereof |
| CN110305847B (zh) * | 2018-07-27 | 2021-05-18 | 赛诺生（深圳）基因产业发展有限公司 | 一种用于治疗肿瘤的基因工程细胞 |
| CN109134665B (zh) * | 2018-08-24 | 2021-06-11 | 上海先博生物科技有限公司 | 一种基于单域抗体的bcma嵌合抗原受体及应用 |
| WO2020113194A2 (en) * | 2018-11-30 | 2020-06-04 | Juno Therapeutics, Inc. | Methods for treatment using adoptive cell therapy |
| EP3902836A4 (en) | 2018-12-18 | 2022-08-31 | Boehringer Ingelheim IO Canada Inc. | FLT3 AGONISTIC ANTIBODIES AND THEIR USES |
| SG11202111130SA (en) | 2019-04-30 | 2021-11-29 | Senti Biosciences Inc | Chimeric receptors and methods of use thereof |
| WO2021054789A1 (ko) * | 2019-09-18 | 2021-03-25 | 주식회사 에스엘바이젠 | 신규 키메라 항원 수용체 암호화 유전자가 형질도입된 유전자 변형 nk 세포주 및 그의 용도 |
| KR102287180B1 (ko) | 2019-10-01 | 2021-08-09 | 충북대학교 산학협력단 | Cd138에 특이적으로 결합하는 키메릭 항원 수용체, 이를 발현하는 면역세포 및 이의 항암 용도 |
| US20230113183A1 (en) * | 2020-04-09 | 2023-04-13 | Autolus Limited | Cell |
| WO2021212069A1 (en) * | 2020-04-17 | 2021-10-21 | City Of Hope | Flt3-targeted chimeric antigen receptor modified cells for treatment of flt3-positive malignancies |
| CN111647071B (zh) * | 2020-06-17 | 2023-05-05 | 深圳豪石生物科技有限公司 | 识别靶细胞表面抗原的t细胞受体及其组合物 |
| CN116410315A (zh) * | 2021-12-31 | 2023-07-11 | 博生吉医药科技(苏州)有限公司 | 一种新型靶向人flt3的嵌合抗原受体修饰的t细胞的构建及应用 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| EP1997891A1 (en) | 1988-09-02 | 2008-12-03 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
| WO1992022324A1 (en) | 1991-06-14 | 1992-12-23 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
| DK1231268T3 (da) | 1994-01-31 | 2005-11-21 | Univ Boston | Polyklonale antistofbiblioteker |
| US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| GB9416721D0 (en) | 1994-08-18 | 1994-10-12 | Short Brothers Plc | A bias yarn assembly forming device |
| US5712149A (en) | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| CA2229043C (en) | 1995-08-18 | 2016-06-07 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| DE19608769C1 (de) | 1996-03-07 | 1997-04-10 | Univ Eberhard Karls | Antikörper BV10A4H2 |
| US6924123B2 (en) | 1996-10-29 | 2005-08-02 | Oxford Biomedica (Uk) Limited | Lentiviral LTR-deleted vector |
| EP1990409A3 (en) | 1999-07-20 | 2011-05-18 | MorphoSys AG | Bacteriophage |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| DK1257632T3 (da) | 2000-02-24 | 2008-01-28 | Xcyte Therapies Inc | Samtidig stimulering og opkoncentrering af celler |
| US7419829B2 (en) | 2000-10-06 | 2008-09-02 | Oxford Biomedica (Uk) Limited | Vector system |
| NZ527937A (en) | 2001-03-13 | 2005-03-24 | Novartis Ag | Stable cell lines to express high levels of lentiviral Gag/Pol proteins for generation of HIV- or BIV- based lentiviral vectors |
| US8034904B2 (en) * | 2002-06-14 | 2011-10-11 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| CA2512647C (en) | 2003-01-07 | 2013-10-08 | Symphogen A/S | Method for manufacturing recombinant polyclonal proteins |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| AR071891A1 (es) * | 2008-05-30 | 2010-07-21 | Imclone Llc | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) |
| US9023996B2 (en) | 2009-12-23 | 2015-05-05 | Synimmune Gmbh | Anti-FLT3 antibodies |
| US9089520B2 (en) * | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
| EP2651442B1 (en) | 2010-12-14 | 2020-04-22 | University of Maryland, Baltimore | Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer |
| WO2013044225A1 (en) | 2011-09-22 | 2013-03-28 | The Trustees Of The University Of Pennsylvania | A universal immune receptor expressed by t cells for the targeting of diverse and multiple antigens |
| EP2817330B1 (en) | 2012-02-22 | 2020-07-08 | The Trustees of the University of Pennsylvania | Use of icos-based cars to enhance antitumor activity and car persistence |
| AU2013312838B2 (en) * | 2012-09-04 | 2018-11-29 | Cellectis | Multi-chain chimeric antigen receptor and uses thereof |
| WO2014124143A1 (en) | 2013-02-06 | 2014-08-14 | Anthrogenesis Corporation | Modified t lymphocytes having improved specificity |
| LT2956175T (lt) | 2013-02-15 | 2017-12-11 | The Regents Of The University Of California | Chimerinis antigeno receptorius ir jo panaudojimo būdai |
| EP2964753B1 (en) * | 2013-03-07 | 2018-04-25 | Baylor College of Medicine | Targeting cd138 in cancer |
| US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| UY35468A (es) * | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| KR102357968B1 (ko) | 2013-10-15 | 2022-02-03 | 더 스크립스 리서치 인스티튜트 | 키메라 항원 수용체 t 세포 스위치 및 이의 용도 |
| CA2927543C (en) | 2013-10-15 | 2021-07-20 | The California Institute For Biomedical Research | Peptidic chimeric antigen receptor t cell switches and uses thereof |
| ES2963718T3 (es) * | 2014-01-21 | 2024-04-01 | Novartis Ag | Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras |
| WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| CN104091269A (zh) | 2014-06-30 | 2014-10-08 | 京东方科技集团股份有限公司 | 一种虚拟试衣方法及虚拟试衣系统 |
| MX2017000646A (es) | 2014-07-15 | 2017-04-27 | Juno Therapeutics Inc | Celulas geneticamente modificadas para terapia celular adoptiva. |
| KR20170074243A (ko) | 2014-10-31 | 2017-06-29 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 변형된 t 세포의 생성 방법 및 조성물 |
| CA2966234A1 (en) | 2014-12-15 | 2016-06-23 | Bellicum Pharmaceuticals, Inc. | Methods for controlled elimination of therapeutic cells |
| EP3608408A1 (en) | 2014-12-15 | 2020-02-12 | Bellicum Pharmaceuticals, Inc. | Methods for controlled activation or elimination of therapeutic cells |
| US9974865B2 (en) | 2015-03-09 | 2018-05-22 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to FLT3 proteins |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| US10286092B2 (en) * | 2015-08-25 | 2019-05-14 | Ucl Business Plc | Detecting a therapeutic cell |
| JP7054924B2 (ja) * | 2015-09-23 | 2022-04-15 | サイトイミューン セラピューティクス， インコーポレイテッド | 免疫療法のためのｆｌｔ３指向ｃａｒ細胞 |
| EP3630841A1 (en) | 2017-06-02 | 2020-04-08 | Pfizer Inc. | Antibodies specific for flt3 and their uses |
| US20210301024A1 (en) | 2018-07-04 | 2021-09-30 | Cytoimmune Therapeutics, Inc. | Compositions and methods for immunotherapy targeting flt3, pd-1, and/or pd-l1 |
-
2016
- 2016-09-23 JP JP2018534523A patent/JP7054924B2/ja active Active
- 2016-09-23 WO PCT/US2016/053577 patent/WO2017053889A2/en not_active Ceased
- 2016-09-23 CN CN201680065509.1A patent/CN109310744A/zh active Pending
- 2016-09-23 KR KR1020187011302A patent/KR20180053744A/ko not_active Ceased
- 2016-09-23 EP EP16849810.3A patent/EP3352784A4/en not_active Withdrawn
- 2016-09-23 CA CA2999037A patent/CA2999037A1/en not_active Abandoned
- 2016-09-23 AU AU2016326721A patent/AU2016326721C1/en not_active Ceased
- 2016-09-23 HK HK19101399.4A patent/HK1258921A1/zh unknown
- 2016-09-23 EP EP19170050.9A patent/EP3569244A1/en not_active Withdrawn
-
2017
- 2017-11-13 US US15/811,608 patent/US10961312B2/en not_active Expired - Fee Related
-
2021
- 2021-03-02 AU AU2021201329A patent/AU2021201329A1/en not_active Abandoned
- 2021-03-11 US US17/199,332 patent/US20210269534A1/en not_active Abandoned
- 2021-11-24 JP JP2021189789A patent/JP2022046461A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018529380A5 (enExample) | ||
| JP2017537622A5 (enExample) | ||
| Barrow et al. | The natural cytotoxicity receptors in health and disease | |
| JP2016502512A5 (enExample) | ||
| RU2014118555A (ru) | Химерные антигенные рецепторы к cd22 | |
| Eagle et al. | ULBP6/RAET1L is an additional human NKG2D ligand | |
| Severson et al. | Junctional adhesion molecule A interacts with Afadin and PDZ-GEF2 to activate Rap1A, regulate β1 integrin levels, and enhance cell migration | |
| Schildberg et al. | Coinhibitory pathways in the B7-CD28 ligand-receptor family | |
| Freedman et al. | Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies | |
| Ito et al. | Killer cell lectin-like receptor G1 binds three members of the classical cadherin family to inhibit NK cell cytotoxicity | |
| Chalupny et al. | ULBP4 is a novel ligand for human NKG2D | |
| Cosman et al. | ULBPs, novel MHC class I–related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor | |
| JP2022109953A5 (enExample) | ||
| JP2018505139A5 (enExample) | ||
| JP2022113880A (ja) | 免疫調節性融合タンパク質およびその使用 | |
| JP2021506243A5 (enExample) | ||
| RU2017130985A (ru) | Фармацевтическая композиция и способ снижения ингибирующего эффекта pd-l1 на т-клетки человека | |
| HRP20220799T1 (hr) | Klaudin-18-2-specifični imunoreceptori i stanični epitopi t | |
| JP2017513478A5 (enExample) | ||
| FI3429618T3 (fi) | Immuunijäjestelmän tarkistuspisteen modulaattorin ja soluun tunkeutuvan peptidin, cargon ja tlr-peptidiagonistin kompleksin yhdistelmä lääketieteelliseen käyttöön | |
| RU2017105515A (ru) | Сигнальная система | |
| RU2015117237A (ru) | Химерные антигенные рецепторы м971 | |
| JP2017518037A5 (enExample) | ||
| JP2021505663A5 (enExample) | ||
| Held‐Feindt et al. | CD70/CD27 ligand, a member of the TNF family, is expressed in human brain tumors |